Adults with relapsing MS rated the Sensoready pen, an autoinjector used to self-administer Kesimpta, for ease of use and ...

Only show cars that can be delivered to me. Please enter your postal code in order to show cars that can be delivered to you.

According to iSpot.TV’s analysis of January TV drug ad spending data, Novartis’ prostate cancer drug Pluvicto swooped in to take the No. 1 spot on the list, with more than $47 million spent ...

Novartis’ efforts to strengthen its wide portfolio by developing breakthrough treatments have made it even more formidable in this space. Kesimpta, Pluvicto, Scemblix, Kisqali, Leqvio and Fabhalta ...

Comments: Sales growth in the quarter was mainly driven by Entresto with $2.2 billion in sales, up 33%, Kesimpta sales of $950 million, up 48%, Kisqali sales of $902 million, up 48%, Cosentyx sales of ...

CNBC Select evaluated dozens of auto loan lenders based on their rates and terms, selection of loan options, car-buying experience and other factors. Below are our picks for the best auto loan ...

The coverage types and limits you choose have a big effect on your car insurance quotes. Most people should get auto insurance quotes that include comprehensive and collision coverage. These coverages ...

Kesimpta is a brand-name subcutaneous injection prescribed for certain forms of multiple sclerosis (MS). Kesimpta begins working right away, but it may take some time for you to notice relief in ...

Novartis AG (NYSE:NVS ... Now, moving to Slide 8. Kesimpta grew 49%, reaching $3.2 billion on the full year. It was outpacing both the B cell and the MS market. We're really pleased by the ...

Key products such as Entresto, Cosentyx, Kesimpta, and Kisqali showed significant sales growth, contributing to the company's robust performance. Novartis AG (NYSE:NVS) has a promising pipeline with ...

Healthcare added 0.4 per cent, with Novartis up 1.9 per cent, after the company posted quarterly adjusted net income that exceeded expectations following strong sales of its heart failure drug ...